RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:HC Wainwright & CoYou are very poorly informed. Bashers like you who think they all know and who talk through their hats make me vomit. It took me 30 seconds to prove you wrong. If you really look, you'll find an impressive list of costs related to partnerships.
SAN DIEGO, CA, CALGARY, AB, June 5, 2019 -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the company has entered into an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates in the US and Canada as EMD Serono, and Pfizer Inc. (NYSE: PFE). The agreement is to co-develop pelareorep in combination with paclitaxel and avelumab*, a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative (HR+ / HER2-) metastatic breast cancer. Oncolytics and Pfizer will share costs associated with the phase 2 clinical trial